Ipsen
Ipsen is a French pharmaceutical company headquartered in Paris, France. It is specialized in oncology, neuroscience and rare diseases. It is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). Ipsen, founded by Henri Beaufour in 1929, has 5,700 employees worldwide, and markets 20 drugs in 115 countries. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Overview. In 1954, the group launched Citrate de Betaïne which is used in the symptomatic treatment  of dyspepsies. The two sons of Henri Beaufour, Albert and Gérard Beaufour, joined the company. In 1961, the first factory was opened in Dreux. In 1976, a research center was started in Milford in Massachusetts in the United States. In 1977, the Smecta was launched. In 1983, the Ipsen Foundation was created, under the aegis of the Fondation de France. In 1992, Ipsen opened a subsidiary in China and later, in 1994, in Russia. In 2007, the group established a partnership with Galderma. In 2013, Ipsen acquired the British company Syntaxin. In 2014, a laboratory was created with the CNRS  in association with the French Alternative Energies and Atomic Energy Commission and the University of Rennes 1. In February 2015, the company announced Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex's lead multiple sclerosis compound, VSN16R. in October 2016, European Commission approved Ipsen's Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death  by 31% in advanced renal cell carcinoma (RCC). In January 2017, Ipsen acquired some assets of Merrimack Pharmaceuticals, including Onivyde. In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion. This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized. In 2019, Ipsen spent close to €388.8 million—15.1% of consolidated sales—on research and development. In July 2020, David Loew was appointed the General Manager and CEO in Ipsen. Research and development. In 2019, Ipsen's R&D expenditure  totaled close to €388.8 million, representing more than 15.1% of group sales. Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Les Ulis Courtaboeuf (France).